Rising painkiller addiction shows drugmakers’ role in shaping medical opinion
Over much of the past decade, the official word on OxyContin was that it rarely posed problems of addiction for patients. The label on the drug, which was approved by the FDA, said the risks of addiction were “reported to be small.”Cognitively impaired and addicted customers are the very very best kind...
...
But according to a Washington Post examination of key scientific papers, a court document and FDA records, many of those claims were developed in studies supported by Purdue Pharma, the maker of OxyContin, or other drug manufacturers. In addition, the conclusions they reached were sometimes unsupported by the data, and when the FDA was struggling to come up with an opioid policy, it turned to a panel populated by doctors who had financial relationships with Purdue and other drugmakers.
But pay no attention to the man behind the curtain.
